NCT06380751
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
AZN — ASTRAZENECA PLC
Phase 3
• Advanced Breast Cancer
TL;DR
Locations updated — PHASE3
What changed
Recent events (last 90 days)
What to check next
- Review CT.gov update history and company disclosures for context.
- Verify whether registry updates lag press releases.